May 6, 2008 -- WuXi PharmaTech (NYSE: WX), the Shanghai-located CRO, has postponed its secondary stock offering, which was proposed one month ago, citing market conditions and the trading price of its ADSs. At the time of the SEC filing, WuXi was selling for $22.15. It has since declined only a small amount to $19.15. More details...
